Reaction: Copanlisib to 1 product

Reaction
Copanlisib
DB12483
Copanlisib M1 metabolite
DBMET03730
Reaction type
oxidation
Direction
Major circulating metabolite?
No
Spontaneous?
No
Activity
active
References
  1. Gerisch M, Schwarz T, Lang D, Rohde G, Reif S, Genvresse I, Reschke S, van der Mey D, Granvil C: Pharmacokinetics of intravenous pan-class I phosphatidylinositol 3-kinase (PI3K) inhibitor [(14)C]copanlisib (BAY 80-6946) in a mass balance study in healthy male volunteers. Cancer Chemother Pharmacol. 2017 Sep;80(3):535-544. doi: 10.1007/s00280-017-3383-9. Epub 2017 Jul 11. [Article]
  2. FDA Approved Drug Products: ALIQOPA (copanlisib) for injection, for intravenous use (September 2023) [Link]
Comments
Not Available
Enzymes
EnzymeKmVmaxRole
Cytochrome P450 3A4Not AvailableNot Availableimplied